What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective.
2021
Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine RD (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
5
References
2
Citations
NaN
KQI